<PAGE>

________________________________________________________________________________
________________________________________________________________________________


                      SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C.   20549
                            ______________________

                                  FORM 10-Q/A

                                 AMENDMENT No.1

       ( X )   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

                   FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1999.

       (    )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

               FOR THE TRANSITION PERIOD FROM __________ TO __________
                         COMMISSION FILE NUMBER: 0-21643
                         ______________________________

                            CV THERAPEUTICS, INC.
            (Exact name of Registrant as specified in its charter)


                 DELAWARE                             43-1570294
         (State of Incorporation)        (I.R.S. Employer Identification No.)


               3172 PORTER DRIVE, PALO ALTO, CALIFORNIA  94304
         (Address of principal executive offices, including zip code)

      Registrant's telephone number, including area code: (650) 812-0585

    Indicate by check whether the Registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.  Yes   X     No

    The number of shares of Common Stock, $0.001 par value, outstanding as
of August 6, 1999 was 12,310,571.


________________________________________________________________________________
________________________________________________________________________________

<PAGE>


                         PART II.  OTHER INFORMATION


ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

    (c)     Exhibits required by Item 601 of Regulation S-K

        EXHIBIT NUMBER                            DESCRIPTION

            10.65                      Stock Purchase Agreement dated
                                        May 5, 1999 between the Company
                                        and Quintiles Transnational Corp.

<PAGE>

            10.66*                      Sales and Marketing Services
                                        Agreement dated May 5, 1999
                                        between the Company, Innovex
                                        Inc. and Quintiles
                                        Transnational Corp.

            10.67*                      Loan Agreement dated May 5,
                                        1999 between the Company and
                                        Quintiles Transnational Corp.

            10.68                      Security Agreement dated May 5,
                                        1999 between the Company and
                                        Quintiles Transnational Corp.

            10.69                       Promissory Note dated May 5,
                                        1999 to Quintiles in principal
                                        amount of $10.0 million.

            10.70                       Promissory Note dated May 5,
                                        1999 to Quintiles Transnational
                                        in principal amount specified
                                        therein.

            10.71                       Amendment to Loan Agreement
                                        dated April 30, 1999 between
                                        the Company and Biotech
                                        Manufacturing Ltd.

            27.1                        Financial Data Schedule

       * Confidential treatment is being sought for portions of this
       exhibit. Brackets indicate portions of the text that have been
       omitted. A separate filing of such omitted text has been made
       with the Commission as part of the Company's application for
       confidential treatment.

    (d)     Reports on Form 8-K

            The Company filed a current report on Form 8-K with the
            Commission on May 19, 1999, with respect to a commercial
            arrangement with Quintiles Transnational Corp. to commercialize
            ranolazine.

<PAGE>

                                  SIGNATURES

    Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf, by the undersigned, thereunto duly authorized.

                                                 CV THERAPEUTICS, INC.


Date: October 1, 1999               By: /s/ CYNTHIA L. CLARK, ESQ.
                                            Cynthia L. Clark, Esq.
                                                General Counsel